Palo Alto VA Institute for Research, VA Palo Alto Heath Care System, Palo Alto, CA.
MAVERIC, VA Boston Healthcare System, Boston, MA.
Blood. 2024 Nov 21;144(21):2248-2265. doi: 10.1182/blood.2023022596.
Genetic studies have identified numerous regions associated with plasma fibrinogen levels in Europeans, yet missing heritability and limited inclusion of non-Europeans necessitates further studies with improved power and sensitivity. Compared with array-based genotyping, whole-genome sequencing (WGS) data provide better coverage of the genome and better representation of non-European variants. To better understand the genetic landscape regulating plasma fibrinogen levels, we meta-analyzed WGS data from the National Heart, Lung, and Blood Institute's Trans-Omics for Precision Medicine (TOPMed) program (n = 32 572), with array-based genotype data from the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (n = 131 340) imputed to the TOPMed or Haplotype Reference Consortium panel. We identified 18 loci that have not been identified in prior genetic studies of fibrinogen. Of these, 4 are driven by common variants of small effect with reported minor allele frequency (MAF) at least 10 percentage points higher in African populations. Three signals (SERPINA1, ZFP36L2, and TLR10) contain predicted deleterious missense variants. Two loci, SOCS3 and HPN, each harbor 2 conditionally distinct, noncoding variants. The gene region encoding the fibrinogen protein chain subunits (FGG;FGB;FGA) contains 7 distinct signals, including 1 novel signal driven by rs28577061, a variant common in African ancestry populations but extremely rare in Europeans (MAFAFR = 0.180; MAFEUR = 0.008). Through phenome-wide association studies in the VA Million Veteran Program, we found associations between fibrinogen polygenic risk scores and thrombotic and inflammatory disease phenotypes, including an association with gout. Our findings demonstrate the utility of WGS to augment genetic discovery in diverse populations and offer new insights for putative mechanisms of fibrinogen regulation.
遗传研究已经确定了许多与欧洲人血浆纤维蛋白原水平相关的区域,但遗传率缺失和非欧洲人群的纳入有限,需要进一步进行具有更高效力和敏感性的研究。与基于阵列的基因分型相比,全基因组测序(WGS)数据提供了对基因组更好的覆盖度和对非欧洲变体更好的代表性。为了更好地了解调节血浆纤维蛋白原水平的遗传景观,我们对美国国立心肺血液研究所转化精准医学研究计划(TOPMed)的 WGS 数据(n=32572)与基于阵列的基因型数据进行了荟萃分析,该数据来自于基因组流行病学中心脏与衰老研究的队列与联盟(Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium,CHARGE)(n=131340),并将其导入 TOPMed 或单倍型参考联盟面板。我们确定了 18 个先前纤维蛋白原遗传研究中未发现的基因座。其中,4 个是由小效应的常见变体驱动的,在非洲人群中的报告次要等位基因频率(MAF)至少高出 10 个百分点。3 个信号(SERPINA1、ZFP36L2 和 TLR10)包含预测的有害错义变体。2 个基因座 SOCS3 和 HPN 分别包含 2 个条件不同的非编码变体。编码纤维蛋白原蛋白链亚基(FGG;FGB;FGA)的基因区域包含 7 个不同的信号,包括一个由 rs28577061 驱动的新信号,该变体在非洲裔人群中很常见,但在欧洲人中极其罕见(MAFAFR=0.180;MAFEUR=0.008)。通过弗吉尼亚州百万老兵计划中的全表型关联研究,我们发现纤维蛋白原多基因风险评分与血栓和炎症性疾病表型之间存在关联,包括与痛风的关联。我们的研究结果表明,WGS 可用于增强对不同人群的遗传发现,并为纤维蛋白原调节的潜在机制提供新的见解。
J Thromb Haemost. 2024-12
Thromb Res. 2024-10
Nucleic Acids Res. 2023-1-6
Arterioscler Thromb Vasc Biol. 2022-8
Am J Hum Genet. 2022-6-2
Clin Rheumatol. 2022-6